Virica Logo

Virica Joins Canadian Pandemic Preparedness Hub

2023-05-10T14:10:30-04:00

Virica is pleased to announce it is part of the Canadian Pandemic Preparedness Hub (CP2H), a new research hub designed to protect Canadians against future pandemics and emerging threats. This multidisciplinary hub is part of an investment by the Government of Canada to grow a strong and competitive biomanufacturing and life sciences sector. “To [...]

Virica Joins Canadian Pandemic Preparedness Hub2023-05-10T14:10:30-04:00

Virica Scientific Founder & CEO Reports out from the ECI Cell Culture Engineering Conference

2023-05-05T09:31:47-04:00

Dr. Jean-Simon Diallo, Virica’s Scientific Founder & CEO, attended and presented on the topic “Overcoming barriers in viral vector manufacturing: Small molecule targeting of antiviral defenses” at the recent Cell Culture Engineering conference. Key takeaways noted for Dr. Jean-Simon Diallo were:  What was surprising:  Several talks made mention of antiviral defenses as an impediment to [...]

Virica Scientific Founder & CEO Reports out from the ECI Cell Culture Engineering Conference2023-05-05T09:31:47-04:00

Government of Ontario Invests in Virica Biotech to Expand Domestic Vaccine Manufacturing Capacity

2023-04-21T09:05:35-04:00

 Ottawa, Canada – April 21, 2023 –Virica Biotech Inc. (“Virica”), a leading supplier and developer of novel viral enhancers, announced today it is expanding its bioprocessing facilities and increasing its capacity to scale up the manufacturing of viral medicines and vaccines. The Government of Ontario is supporting the expansion at sites in Ottawa with [...]

Government of Ontario Invests in Virica Biotech to Expand Domestic Vaccine Manufacturing Capacity2023-04-21T09:05:35-04:00

Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer

2023-01-05T10:04:05-05:00

Ottawa, Canada- January 5th, 2023- Virica Biotech Inc. ("Virica"), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica’s commercial efforts to drive [...]

Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer2023-01-05T10:04:05-05:00

Virica Biotech to be Showcased in Xtalks Webinar: Process Intensification in AAV Gene Therapy

2022-11-04T10:15:36-04:00

Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on process intensification in the manufacturing of adeno associated virus (AAV) vectors. Tune into this free webinar to learn [...]

Virica Biotech to be Showcased in Xtalks Webinar: Process Intensification in AAV Gene Therapy2022-11-04T10:15:36-04:00

Virica Biotech Wins Top Abstract Award at ISCT 2022

2022-08-03T09:22:41-04:00

Virica Biotech Awarded Best Abstract at ISCT 2022-San Francisco Our Data Scientist, Andrea Vervoot and VP of Scientific Operations, JonDavid De Jong represented Virica at International Society of Cell & Gene Therapy (ISCT) 2022 in San Francisco. Andrea Vervoot's abstract presentation on the Bioprocess Modelling of Upstream Viral Vector Production Enhancement won the Best Elevator [...]

Virica Biotech Wins Top Abstract Award at ISCT 20222022-08-03T09:22:41-04:00

Virica Biotech Announces Collaboration with the Government of Canada

2022-05-02T07:56:49-04:00

For Immediate Release Virica Biotech Announces Collaboration with the Government of Canada to Make Gene Therapies More Accessible and Affordable for Canadians  Download full press release here. Ottawa, Canada – May 2, 2022 –Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, [...]

Virica Biotech Announces Collaboration with the Government of Canada2022-05-02T07:56:49-04:00

Virica Biotech Announces R&D Partnership with Oxford BioMedica

2022-02-04T08:52:54-05:00

OTTAWA ,Canada– January 24th, 2022 – Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's [...]

Virica Biotech Announces R&D Partnership with Oxford BioMedica2022-02-04T08:52:54-05:00
Go to Top